| Literature DB >> 9408477 |
Abstract
The type of seizure measurement selected should be tailored to the needs of the clinical trial. These needs change as the development of the investigational agent moves along. Protocol designers who look toward nontraditional outcome measures might acquire valuable data that could be used to differentiate their drug from other new treatments. Most importantly, as clinical trials evolve into effectiveness studies, clinicians are provided with useful data on which to base selection of a drug of first choice to treat each type of seizure disorder.Entities:
Mesh:
Substances:
Year: 1998 PMID: 9408477
Source DB: PubMed Journal: Adv Neurol ISSN: 0091-3952